Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

Introduction: Central nervous system (CNS) metastases remain a common challenge in patients with ALK-positive NSCLC. We previously reported reinduction of CNS responses using dose-intensified alectinib in two patients with CNS progression on standard-dose alectinib. Nevertheless, this strategy has n...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Justin M. Cheung, MD, Jiyoon Kang, DO, Beow Y. Yeap, ScD, Jennifer L. Peterson, BS, Andrew Do, BS, Justin F. Gainor, MD, Subba R. Digumarthy, MD, Jessica J. Lin, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Subjects:	Alectinib CNS Brain metastases ALK NSCLC
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324000158